ENDRA Life Sciences Inc.
NDRANASDAQHealthcare● Active
$4.27
+$0.04(+0.95%)
Market Cap$3213734
P/E Ratio—
52W High$11.96
52W Low$2.96
ENDRA Life Sciences Inc. (NDRA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NDRA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$1.09
Est. -$1.23 · +11.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
NDRA reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.84 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 18, 2026 | -$1.23 | -$1.09 | +11.4% | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$1.23 | -$3.26 | -165.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$1.95 | -$1.75 | +10.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$2.27 | -$1.71 | +24.7% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$3.91 | -$2.59 | +33.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$4.10 | -$9.40 | -129.3% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 15, 2024 | -$62.30 | -$5.85 | +90.6% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.84
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Beat
EPS Actual
-$1.09
EPS Est.
-$1.23
EPS Surpr.
+11.4%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$3.26
EPS Est.
-$1.23
EPS Surpr.
-165.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$1.75
EPS Est.
-$1.95
EPS Surpr.
+10.3%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$1.71
EPS Est.
-$2.27
EPS Surpr.
+24.7%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$2.59
EPS Est.
-$3.91
EPS Surpr.
+33.8%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$9.40
EPS Est.
-$4.10
EPS Surpr.
-129.3%
Revenue
$0.00B
Q4 FY2024
Nov 15, 2024Beat
EPS Actual
-$5.85
EPS Est.
-$62.30
EPS Surpr.
+90.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q3 FY2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q2 FY2027 | $-0.76 | $-0.76 | $-0.76 | 1 |
| Q1 FY2027 | $-0.80 | $-0.80 | $-0.80 | 1 |
| Q4 FY2026 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Q3 FY2026 | $-0.84 | $-0.84 | $-0.84 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 18, 2026 | +11.4% | $5.05 | $5.41 | +7.13% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -165.0% | $4.68 | $4.65 | -0.64% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +10.3% | $6.57 | $6.70 | +1.98% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +24.7% | $4.38 | $4.44 | +1.37% |
| ▲ Q2 FY2025 | May 15, 2025 | +33.8% | $3.13 | $3.21 | +2.56% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -129.3% | $4.05 | $4.10 | +1.23% |
| ▲ Q4 FY2024 | Nov 15, 2024 | +90.6% | $5.29 | $4.54 | -14.18% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -14.2% | $15.65 | $15.58 | -0.45% |
Q2 FY2026+7.13%
Report Date
May 18, 2026
EPS Beat/Miss
+11.4%
Price Before
$5.05
Price After
$5.41
Q1 FY2026-0.64%
Report Date
Mar 31, 2026
EPS Beat/Miss
-165.0%
Price Before
$4.68
Price After
$4.65
Q4 FY2025+1.98%
Report Date
Nov 14, 2025
EPS Beat/Miss
+10.3%
Price Before
$6.57
Price After
$6.70
Q3 FY2025+1.37%
Report Date
Aug 14, 2025
EPS Beat/Miss
+24.7%
Price Before
$4.38
Price After
$4.44
Q2 FY2025+2.56%
Report Date
May 15, 2025
EPS Beat/Miss
+33.8%
Price Before
$3.13
Price After
$3.21
Q1 FY2025+1.23%
Report Date
Mar 31, 2025
EPS Beat/Miss
-129.3%
Price Before
$4.05
Price After
$4.10
Q4 FY2024-14.18%
Report Date
Nov 15, 2024
EPS Beat/Miss
+90.6%
Price Before
$5.29
Price After
$4.54
Q3 FY2024-0.45%
Report Date
Aug 22, 2024
EPS Beat/Miss
-14.2%
Price Before
$15.65
Price After
$15.58
Avg Beat Reaction-0.23%
Avg Miss Reaction+0.05%
Beat Rate5 / 8 quarters
Largest Move-14.18% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NDRA ends December
ENDRA Life Sciences Inc. (NDRA) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-1.09 — beating the analyst consensus of $-1.23 by +11.4%. The next NDRA earnings date is expected around September 1, 2026.
Each quarter, investors track NDRA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NDRA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NDRA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NDRA earnings · 5 questionsENDRA Life Sciences Inc.'s next earnings report is expected around September 1, 2026. NDRA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NDRA historically reports after market close (AMC).
NDRA earnings datewhen is NDRA earningsNDRA next earnings datewhen does NDRA report earningsNDRA earnings calendar
▸ Source: FMP · ENDRA Life Sciences Inc. SEC filings · US GAAP · ENDRA Life Sciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026